Recent

% | $
Quotes you view appear here for quick access.

Hemispherx Biopharma, Inc. Message Board

helterskelterheb 52 posts  |  Last Activity: Aug 20, 2015 3:23 PM Member since: Jul 21, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    HEB dilution over the years

    by pharmainvestor1998 Aug 18, 2015 2:15 PM
    helterskelterheb helterskelterheb Aug 20, 2015 3:23 PM Flag

    While hebmaster's "hedgies" are entirely imaginary, HEB's dilution has been only too real.

  • Reply to

    HEB dilution over the years

    by pharmainvestor1998 Aug 18, 2015 2:15 PM
    helterskelterheb helterskelterheb Aug 20, 2015 12:25 PM Flag

    I have never gained or lost a penny on HEB.

    But the retail investors who own 92% of HEB's shares are the big losers with all of this dilution.

    Are you aware of the effects of dilution on share price? Or do you need a tutorial for this?

  • Reply to

    HEB dilution over the years

    by pharmainvestor1998 Aug 18, 2015 2:15 PM
    helterskelterheb helterskelterheb Aug 20, 2015 12:17 PM Flag

    And with the outstanding going above 300,000,000 over the coming year, you can start to adjust your projected share prices down accordingly.

  • Reply to

    HEB dilution over the years

    by pharmainvestor1998 Aug 18, 2015 2:15 PM
    helterskelterheb helterskelterheb Aug 20, 2015 12:12 PM Flag

    With another 60 million share dump on the near horizon, we know that SEC filings this time next year will probably show greater than 300,000,000 shares outstanding, barring a reverse split.

  • helterskelterheb by helterskelterheb Aug 17, 2015 6:06 PM Flag

    J Psychosom Res. 2015 Jul 17.
    A comparison of patients with Q fever fatigue syndrome and patients with chronic fatigue syndrome with a focus on inflammatory markers and possible fatigue perpetuating cognitions and behaviour.
    Keijmel SP1,
    Abstract
    METHODS:
    Data from two independent prospective studies on QFS (n=117) and CFS (n=173), respectively, were pooled and analyzed.
    RESULTS:
    QFS patients were less often female, had a higher BMI, and had less often received treatment for depression before the onset of symptoms. After controlling for symptom duration and correcting for differences in diagnostic criteria for QFS and CFS with respect to the level of impairment and the presence of additional symptoms, differences in the proportion of females and BMI remained significant. After correction, QFS patients were also significantly older. In all analyses QFS patients were as fatigued and distressed as CFS patients, but reported less additional symptoms. QFS patients had stronger somatic attributions, and higher levels of physical activity. No differences were found with regard to inflammatory markers and in other fatigue-related cognitive-behavioural variables. The relationship between cognitive-behavioural variables and fatigue, previously established in CFS, could not be confirmed in QFS patients with the exception of the negative relationship between physical activity and fatigue.
    CONCLUSION:
    Differences and similarities between QFS and CFS patients were found. Although the relationship between perpetuating factors and fatigue previously established in CFS could not be confirmed in QFS patients, the considerable overlap in fatigue-related cognitive-behavioural variables and the relationship found between physical activity and fatigue may suggest that behavioural interventions could reduce fatigue severity in QFS patients.

  • helterskelterheb by helterskelterheb Aug 17, 2015 6:02 PM Flag

    It shows how activation of TLR3 promotes oral inflammation.

    "J Dent Res. 2015 Aug
    Necrosis-induced TLR3 Activation Promotes TLR2 Expression in Gingival Cells.
    Mori K1, Yanagita M2, Hasegawa S1,
    Abstract
    Damage-associated molecular patterns (DAMPs), endogenous molecules released from injured or dying cells, evoke sterile inflammation that is not induced by microbial pathogens. Periodontal diseases are infectious diseases caused by oral microorganisms; however, in some circumstances, DAMPs might initiate inflammatory responses before host cells recognize pathogen-associated molecular patterns. Here, we showed that the necrotic cell supernatant (NCS) functioned as an endogenous danger signal when released from necrotic epithelial cells exposed to repeat freeze thawing. The NCS contained RNA and stimulated the production of inflammatory cytokines interleukin 6 (IL-6) and IL-8 from gingival epithelial cells and gingival fibroblasts. Targeted knockdown of Toll-like receptor 3 (TLR3) in these cells significantly suppressed the ability of the NCS to induce IL-6 and IL-8 production. Epithelial cells and fibroblasts recognized the NCS from heterologous cells. Interestingly, the activation of TLR3, rather than other TLRs, induced TLR2 mRNA expression and proteins in gingival epithelial cells, and pretreatment with the NCS or polyinosinic:polycytidylic acid (Poly(I:C)), a strong TLR3 activator, enhanced inflammatory cytokine production induced by subsequent stimulation with Porphyromonas gingivalis (P. gingivalis) lipopolysaccharide, a TLR2 agonist. Moreover, the NCS reduced the expression of epithelial tight junction molecules zona occludens 1 and occludin and increased the permeability of epithelial tight junctions. These findings suggest that endogenous danger signal molecules such as self-RNA released from necrotic cells are recognized by TLR3 and that a subsequent increase of TLR2 expression in periodontal compartments such as gingival epithelial cells and gingival fib

  • helterskelterheb by helterskelterheb Aug 17, 2015 5:53 PM Flag

    "For the six months ended June 30, 2015, the Company had sold 38,919,883 shares of the EDA that resulted in net cash proceeds of approximately $9,293,000 after direct expenses along with commissions paid to Maxim for approximately $287,000."

    The share dumping has eased off a little bit because they have run out of shares to dump.

    Once the reduced quorum of shareholders votes to permit another 60,000,000 shares to be dumped, the dumping will resume in earnest.

  • helterskelterheb by helterskelterheb Aug 3, 2015 1:09 PM Flag

    Trials. 2015 Jul 26;16:314. doi: 10.1186/s13063-015-0857-0.
    Acupuncture for chronic fatigue syndrome and idiopathic chronic fatigue: a multicenter, nonblinded, randomized controlled trial.

    Abstract
    BACKGROUND:
    The causes of chronic fatigue syndrome (CFS) and idiopathic chronic fatigue (ICF) are not clearly known, and there are no definitive treatments for them. Therefore, patients with CFS and ICF are interested in Oriental medicine or complementary and alternative medicine. For this reason, the effectiveness of complementary and alternat
    Group A showed significantly lower FSS scores than Group C at 5 weeks (P = 0.023). SRI scores were significantly lower in the treatment groups than in the control group at 5 (Group A, P = 0.032; B, P less than 0.001) and 13 weeks (Group A, P = 0.037; B, P less than 0.001). Group B showed significantly lower BDI scores than Group C at 13 weeks (P = 0.007). NRS scores from the treatment groups were significantly reduced compared to control at 5 (Group A and B, P leive treatments should be verified. We investigated the effectiveness of two forms of acupuncture added to usual care for CFS and ICF compared to usual care alone.
    METHODS:
    A three-arm parallel, non-blinded, randomized controlled trial was performed in four hospitals. We divided 150 participants into treatment and control groups at the same ratio. The treatment groups (Group A, body acupuncture; Group B, Sa-am acupuncture) received 10 sessions for 4 weeks. The control group (Group C) continued usual care alone. The primary outcome was the Fatigue Severity Scale (FSS) at 5 weeks after randomization. Secondary outcomes were the FSS at 13 weeks and a short form of the Stress Response Inventory (SRI), the Beck Depression Inventory (BDI), the Numeric Rating Scale (NRS), and the EuroQol-5 Dimension (EQ-5D) at 5 and 13 weeks.
    RESULTS:ss than 0.001) and 13 weeks (Group A, P = 0.011; B, P = 0.002).

  • Reply to

    Share blizzard

    by rosie_bengali Jul 6, 2015 5:28 PM
    helterskelterheb helterskelterheb Jul 31, 2015 11:37 AM Flag

    I haven't seen anyone calling for a share blizzard in recent years. But when i1again predicted it, it looks like his prediction was a good one.

    I 'm not sure why jonjonson/hebmaster/manofscyence is always bringing up this accurate prediction by i1again.

  • helterskelterheb helterskelterheb Jul 15, 2015 1:57 PM Flag

    So, why do the pumpers like to imagine that a journalist named Adam is in charge of their imaginary hedge fund?

  • Reply to

    James Ripple

    by tomtomgolf Jul 14, 2015 7:18 AM
    helterskelterheb helterskelterheb Jul 14, 2015 11:16 AM Flag

    The truth is that these class action lawsuits are usually more for the benefit of the lawyers than the plantiffs. They will usually settle for the maximum amount of the company's insurance coverage.

    Again, HEB's accepts this as the cost of doing business they way that they were taught by Stratton Oakmont.

  • Reply to

    James Ripple

    by tomtomgolf Jul 14, 2015 7:18 AM
    helterskelterheb helterskelterheb Jul 14, 2015 10:53 AM Flag

    LOL, that was another lawsuit that HEB had to settle.

    Every big HEB pump-and-dump ends in a shareholder lawsuit. HEB just accepts that as the cost of doing business as a pump-and-dump operation.

    If you were to take time to become familiar with HEB's sordid history, you would know these things.

  • Reply to

    James Ripple

    by tomtomgolf Jul 14, 2015 7:18 AM
    helterskelterheb helterskelterheb Jul 14, 2015 10:13 AM Flag

    That recent settlement was for the doomed 2012 NDA, not the doomed 2009 NDA.

    If you had read Judge Yohn's assessment of the case in his opinion against HEB's motion to dismiss, you would understand why HEB was eager to settle this one about their 2012 deception.

  • Reply to

    James Ripple

    by tomtomgolf Jul 14, 2015 7:18 AM
    helterskelterheb helterskelterheb Jul 14, 2015 9:30 AM Flag

    HEB has had other flunkies who have promoted HEB using their real names before.

    In the 2009 NDA pump and dump, they had Matt Garza pushing HEB and even doing a faux interview with Carter, (kind of like Rippel's "interview" with Equels). For that NDA, (which was doomed at the time it was submitted), HEB submitted a late chemistry amendment that reset the clock. HEB was not candid about the reason for this delay and tried to insinuate that the delay was due to issues at the FDA. In the faux interview, Garza portrayed Carter as hinting that this delay and the fact that Carter had not heard anything from the FDA was somehow a good omen for approval.

    After that, they had a clown named Vinny who worked for Stock Traders Press, (an outfit run by Stratton Oakmont alums), promote HEB using his real name on this board.

    Even jonj49307 has at times used his real name to promote HEB, and he confesses to being paid to post here.

    I don't see how being an HEB flunky who uses his real name actually increases credibility. HEB is such a lousy company that anyone who promotes it slimes themselves in the process.

  • Reply to

    James Ripple

    by tomtomgolf Jul 14, 2015 7:18 AM
    helterskelterheb helterskelterheb Jul 14, 2015 8:52 AM Flag

    Someone who spends time on twitter, stocktwits and Seeking Alpha to promote HEB has already tarnished their reputation beyond repair.

  • Reply to

    James Ripple

    by tomtomgolf Jul 14, 2015 7:18 AM
    helterskelterheb helterskelterheb Jul 14, 2015 8:47 AM Flag

    Yes, your professional reputation as a yoga instructor and as an English teacher in Bogota are certainly precious jewels that must be protected at all costs.

    As for why anyone would criticize HEB here, I think that anyone who reads up on the HEB story and who has a little bit of time and an altruistic streak would naturally be inclined to warn innocent investors about HEB.

  • Reply to

    James Ripple

    by tomtomgolf Jul 14, 2015 7:18 AM
    helterskelterheb helterskelterheb Jul 14, 2015 8:12 AM Flag

    I'm sorry, but HEB is such a manifestly lousy stock, that it strains credulity to imagine any non-brain damaged person writing anything good about it unless they are getting some secondary gain for debasing themselves in this manner.

  • Reply to

    James Ripple

    by tomtomgolf Jul 14, 2015 7:18 AM
    helterskelterheb helterskelterheb Jul 14, 2015 8:07 AM Flag

    jonj49307 has already confessed to being compensated for promoting HEB on this board.

    Is the person or entity that has hired jonj49307 the same one who has engaged Rippel's services?

  • Reply to

    James Ripple

    by tomtomgolf Jul 14, 2015 7:18 AM
    helterskelterheb helterskelterheb Jul 14, 2015 8:01 AM Flag

    So, what deal is Equels offering to Rippel to promote HEB?

  • Reply to

    jonjonson/JohnnyD trolls CFS patient boards

    by helterskelterheb Jun 12, 2015 12:36 PM
    helterskelterheb helterskelterheb Jun 12, 2015 1:35 PM Flag

    When one CFS patient expressed skepticism about XMRV and CFS and Ampligen, jonjonson got very pissy.

    "pine108kell said: ↑
    No one has even proven a link between CFS and XMRV. What's more, as far as I know, no one one has shown that Ampligen has any effect on XMRV. I don't know why a research scientist who, as far as I know, does not treat any patients, would make public speculations such as this."

    "You are aware are you not that heb is the only company to treat xmrv patients in a phase III????

    WPI did a retrospective study with ampligen.... very sound science..... blinded to be sent to the fda....

    which showed clearly ampligen had an effect on xmrv...

    I dont see why a research scientist who has the right data couldnt form an opinion if it works or not.....

    Your post seems narrow minded at best.....

    jonjonson, Feb 24, 2011"

    His posts at that time in no way are consistent with his assertion today that "I said to the end.....that if proper controls were added and it passed muster..... I would be a believer......"

    Nope, not at all.

HEB
0.161-0.006(-3.65%)Aug 28 4:00 PMEDT